Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

ClinicalTrials.gov ID: NCT03350035

Public ClinicalTrials.gov record NCT03350035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

Study identification

NCT ID
NCT03350035
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Marinus Pharmaceuticals
Industry
Enrollment
17 participants

Conditions and interventions

Interventions

  • IV Ganaxolone active Drug
  • IV Placebo, non-active Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 18, 2018
Primary completion
Sep 17, 2019
Completion
Sep 17, 2019
Last update posted
Mar 8, 2023

2018 – 2019

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Nemours/AI duPont Hospital for Children Wilmington Delaware 19803
Nicklaus Children's Hospital Miami Florida 33155
Grady Hospital Atlanta Georgia 30303
Oschner Clinic Foundation New Orleans Louisiana 70121
Brigham and Women's Hospital Boston Massachusetts 02115
Henry Ford Hospital Detroit Michigan 48202
Duke Medical Center Durham North Carolina 27710
Allegheny General Hospital Pittsburgh Pennsylvania 15212

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03350035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 8, 2023 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03350035 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →